尼莫地平口服与静脉给药治疗动脉瘤性蛛网膜下腔出血疗效的系统评价  

Systematic Review on the Efficacy of Enteral Versus Intravenous Nimodipine in Treating Aneurysmal Subarachnoid Hemorrhage

作　　者：陆富泉 梅育嘉[1] 罗杰峰[1] 

机构地区：[1]广西医科大学第一附属医院神经内科,南宁530021

出　　处：《医学综述》2015年第3期520-521,525,共3页Medical Recapitulate

摘　　要：目的系统评价尼莫地平口服和静脉给药治疗动脉瘤蛛网膜下腔出血(a SAH)的疗效。方法检索Pubmed、Embase、Cochrane Database、Ovid、CBM、VIP、CKMB,收集尼莫地平口服和静脉给药治疗a SAH的前瞻性随机对照试验(RCT),对符合纳入标准的研究进行Meta分析。结果共纳入两项RCT研究,277例患者。Meta分析结果表明,口服组与静脉组相比,治疗a SAH后延迟性缺血性神经功能障碍、迟发性脑梗死及格拉斯哥预后评分的情况差异无统计学意义(P>0.05)。结论该系统评价表明尼莫地平口服与静脉给药治疗a SHA疗效的差异无统计学意义。Objective To evaluate the curative effect and safety of enteral and intravenous nimodipine in the treatment of aneurysmal subarachnoid hemorrhage（ a SAH）. Methods Randomized controlled trials（ RCT） of treatment for a SAH with enteral and intravenous nimodipine were searched from Pubmed,Embase,the Cochrane Database,Ovid,CBM,VIP,CKMB. Studies met the inclusion criteria were conducted meta-analysis. Results Two RCTs were included,involving 277 patients. Results of meta-analysis showed that the incidence of delayed ischemic neurological deficits,delayed cerebral infarction,Glasgow prognostic scores has no statistically significant differences between enteral and intravenous groups（ P 0. 05）. Conclusion Systematic review showed enteral and intravenous nimodipine in treating a SAH has no statistically significant difference in clinical efficacy.

关 键 词：蛛网膜下腔出血 尼莫地平 系统评价 

分 类 号：R743.35[医药卫生—神经病学与精神病学]